Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Stemline Therapeutics, Inc.
Xencor, Inc.
Fred Hutchinson Cancer Center
Mayo Clinic
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)